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Antigen-Specific CD8 T Cells Can Eliminate
Antigen-Bearing Keratinocytes with Clonogenic
Potential via an IFN-c-Dependent Mechanism
Rachel L. De Kluyver1,3, Linnea Moritz1, Craig A. Harris1, Hiroaki Azukizawa2 and Ian H. Frazer1
The immune system surveys the skin for keratinocytes (KCs) infected by viruses or with acquired genetic
damage. The mechanism by which T cells mediate KC elimination is however undefined. In this study we show
that antigen-specific CD8 Tcells can eliminate antigen-bearing KCs in vivo and inhibit their clonogenic potential
in vitro, independently of the effector molecules perforin and Fas-ligand (Fas-L). In contrast, IFN-g receptor
expression on KCs and T cells producing IFN-g are each necessary and sufficient for in vitro inhibition of
KC clonogenic potential. Thus, antigen-specific cytotoxic T lymphocytes (CTLs) may mediate destruction
of epithelium expressing non-self antigen by eliminating KCs with potential for self-renewal through an
IFN-g-dependent mechanism.
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INTRODUCTION
Epithelial tumors comprise over 50% of human malignancies,
and can express a range of viral and neo-self antigens.
Immunotherapy directed at tumor-specific antigens has been
mooted as therapy for epithelial squamous cancer (Urosevic
and Dummer, 2002). Successful immunotherapy induces a
range of antigen-specific immune responses, including CD8
effector T cells that are widely held to be responsible for
control of tumor growth in vivo. Major histocompatibility
complex (MHC) class I-restricted CD8 T cells induced by
immunization can induce regression of tumors expressing the
E7 protein of human papillomavirus type 16 (HPV16-E7)
(Chen et al., 1991). However, when HPV16-E7 is presented
by epithelial cells in skin, such immunization is insufficient
to eradicate antigen-expressing cells (Dunn et al., 1997).
Cell death induced by CD8 T cells is generally evaluated in
short-term in vitro lysis assays that most effectively show
rapid lytic mechanisms based on perforin (Trapani and
Smyth, 2002). In vivo, elimination of epithelial grafts, even
from primed animals, occurs over several days or weeks.
Thus, distinct effector mechanisms may be responsible for
elimination of transplantable tumors versus elimination of
antigen-bearing skin.
Alternate mechanisms for CD8 T-cell-mediated induction
of epithelial cell death are well recognized. These include
cytolysis after Fas/Fas-ligand (Fas-L) interactions (Daehn
et al., 2006), which is generally deemed to require 6–8hours,
and tumor necrosis factor-a (TNF-a) and TNF-related
apoptosis-inducing ligand-mediated differentiation and apop-
tosis (Basile et al., 2001). IFN-g has also been shown to kill
transformed epithelial cell lines in vitro (Konur et al., 2005).
We therefore decided to examine the effects of various T-cell
effector mechanisms on the clonogenic potential of non-
malignant keratinocytes (KCs) and on the survival of skin
expressing non-self antigen only in KCs. This study distin-
guishes itself from most studies on mechanism of skin
allograft rejection in that non-self antigens are expressed
only by epithelial cells, and not by antigen-presenting cells,
vascular, or stromal cells, and can therefore be cross-
presented but not directly presented by these cells.
RESULTS
Requirements for rejection of skin grafts expressing antigen in
KCs
We first defined the role of MHC class I-restricted T cells in
destruction of epithelium expressing antigen in KCs. Skin
from mice expressing a single MHC class I epitope of
ovalbumin (SIINFEKL) in KCs from a keratin 14 promoter
(K14-OVAp) was grafted onto mice expressing an irrelevant
peptide, SIYRYYGL, as a transgene in the same expression
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cassette (K14-SIYp). Grafts from K14-OVAp animals were
rejected at low frequency by untreated K14-SIYp animals
(Figure 1a), whereas grafts from non-transgenic animals were
not rejected (data not shown). Adoptive transfer of antigen-
specific spleen cells at the time of grafting increased the rate of
graft rejection when compared with untreated recipients,
although the increase did not reach statistical significance.
However, adoptive transfer of antigen-specific effector cells,
combined with immunization with OVA, resulted in rejection of
all K14-OVAp skin grafts by day 20 after grafting. Thus, induction
of MHC class I-restricted effector cells by skin expressing a
minimal cytotoxic T lymphocyte (CTL) peptide in KCs is
inefficient. However, MHC class I peptide-restricted T cells
activated by immunization are sufficient to destroy epithelium
expressing a single MHC class I-restricted peptide in KCs.
To establish whether antigen in epithelial cells must
necessarily be presented through MHC class I to enable
effector function, skin from mice expressing membrane-
associated OVA protein from a keratin 5 promoter
(K5-mOVA), and either expressing b2-microglobulin (b2m)
or b2m deficient was grafted to naive C57 recipients. K5-
mOVA b2m
þ /þ grafts were rapidly rejected, whereas K5-
mOVA b2m
/ grafts generally survived (Figure 1b). Thus,
KCs expressing full-length OVA and potentially presenting a
diversity of MHC class I and II epitopes, in contrast to KCs
expressing a minimal OVA CTL epitope, can mediate priming
of MHC class I-restricted T cells. Taken together, the data also
show that antigen-primed MHC class I-restricted T cells are
necessary and sufficient to affect rejection of epithelium
expressing antigen in KCs.
Perforin and Fas-L are not required for T-cell-mediated
inhibition of KC colony formation in vitro
To determine the mechanism by which MHC class I-
restricted CD8 T cells kill KCs, we assessed whether T-cell
lines could alter the ability of freshly isolated KCs with
colony-forming potential to form colonies in vitro (Figure 2).
Primary cultures of KCs pulsed with the minimal CTL epitope
peptide of the E7 protein of HPV16 (RAHYNIVTF), or
expressing E7 as a transgene, were cultured with RAHY-
NIVTF-specific CD8þ CTL lines, or as a control, with an
allospecific CTL line. Allospecific CTLs effectively killed EL4
and C57 KC targets, and inhibited colony formation of C57
KC (Figure 2a). Similarly, E7 peptide-specific CTLs exclu-
sively killed peptide-pulsed EL4 cells, and inhibited colony
formation of peptide-pulsed and K14-E7 KCs (Figure 2b).
Killing of peptide-pulsed EL4 cells and inhibition of KC
colony formation by E7 peptide-specific CTL lines was then
compared with inhibition with E7-specific CTL lines gener-
ated from C57 animals singly deficient in perforin, or Fas-L.
Fas-L/ CTLs killed EL4 cells and inhibited KC colony
formation as effectively as competent CTLs. Perforin/ CTLs
were impaired in their ability to kill EL4 cells (Figure 2c), but
neither perforin/ CTLs (Figure 2c) nor perforin CTLs
combined with antibody-mediated Fas-L blockade inhibited
KC colony formation. Thus, inhibition of KC clonogenic
potential in vitro requires neither Fas/Fas-L interactions nor
perforin.
Perforin and Fas-L are dispensable for rejection of E7 skin grafts
The in vitro results described above show that killing of KCs
by MHC class I-restricted T cells is not dependent on perforin.
To analyze the role of perforin or Fas-L in rejection of skin
grafts expressing HPV16-E7 as the target antigen, perforin/
and Fas-L/ mice carrying the b-chain of a TCR specific for
E7 as a transgene were bred from parent TCR transgenic
animals. Spleen cells from E7TCR transgenic animals were
transferred to syngeneic mice that were grafted with K14-E7
skin, and immunized with E7 protein. Rejection of K14-E7
skin grafts, but not control C57 grafts, was observed with Fas-
L and perforin-replete T-cell lines (Figure 3b), and was also
observed at similar frequency on animals receiving E7TCR
spleen cells deficient in Fas-L or perforin (Figure 3a).
Adoptive transfer of E7TCR spleen cells or E7TCR spleen
cells deficient in either Fas-L or perforin to graft recipients,
without concurrent E7 immunization, or immunization of
graft recipients without concurrent cell transfer, did not
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Figure 1. Skin grafts expressing a minimal cytotoxic T lymphocyte (CTL)
epitope are sensitive to rejection. (a) Skin from K14-OVAp mice was grafted
onto K14-SIYp recipients that were, at the time of grafting, otherwise
untreated (’, n¼ 13), given 5 106 Rag1/OVA TCR splenocytes by
adoptive transfer (AT only, ., n¼ 9), or given splenocytes and additionally
immunized with OVA (ATþ IM, J, n¼15). Graft survival was subjected to
Kaplan–Meyer analysis; survival of K14-OVAp skin grafts on ATþ IM
recipients compared with untreated or AT-only recipients was significantly
shorter (Po0.0001). (b) Skin from b2-microglobulin / mice with (&,
n¼ 16) or without co-expression of membrane-anchored OVA (~, n¼8) or
skin from K5-mOVA mice (’, n¼ 9) was grafted onto C57 recipients.
Graft survival was subjected to Kaplan–Meyer analysis; survival of b2-
microglobulin þ /þ K5-mOVA grafts was significantly shorter (Po0.005)
than survival of the other grafts.
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induce graft rejection (Figure 3a). Taken together, these data
indicate that expression of the cytotoxic effector molecules
Fas-L and perforin by antigen-specific CD8þ T cells is not
necessary for rejection of skin grafts expressing antigen in
KCs, replicating in vivo the findings for elimination of KC
clonogenic potential by antigen-specific T-cell lines in vitro.
Interferon-c induces apoptosis of KCs
As perforin-mediated lysis was not necessary for elimination
of KCs by CD8 T cells in vitro or of skin grafts in vivo, we
examined whether a soluble factor produced by activated
CD8 T cells might mediate impaired KC colony-formation
potential (Figure 4). KCs were exposed in vitro to super-
natants from T cells co-cultured with peptide-pulsed irra-
diated splenocytes or, as a control, T cells stimulated with
irradiated splenocytes without added peptide. Only super-
natants from T cells co-cultured with splenocytes expressing
cognate antigen could inhibit colony formation (Figure 4a).
We hypothesized that IFN-g, which is known to affect KC
proliferation and differentiation, might be responsible for the
observed inhibition of colony formation. Addition of recom-
binant IFN-g inhibited KC colony formation in dose-
dependent manner, with peak inhibition observed with
exposure of KCs to 100 ng IFN-g per ml (Figure 4b). IFN-g-
mediated colony inhibition could largely be reversed by
addition of the pan-caspase inhibitor zVAD-fmk but not by
addition of a control analog zFA (Figure 4e). T-cell/
splenocyte-conditioned supernatants typically contained
6–7 mgml–1 IFN-g as assayed by ELISA, and were expected
<1%
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Figure 2. T-cell-mediated inhibition of keratinocyte (KC) growth. T-cell lines
were tested for ability to lyse cell lines in a 4-hour chromium-release assay
(left panel) and to inhibit colony formation from primary KCs (right panel).
(a) H-2d anti-H-2b T-cell line at 10:1 effector to target (E/T) ratio. Left panel:
lysis of P815 cells (H-2d), EL4 cells (H-2b), and primary KCs (H-2b). Right
panel: inhibition of colony formation from H-2d, H-2b, or H-2q KCs. (b) H-2b/
E7 peptide-specific T-cell line. Left panel: lysis of EL4 cells, with or without
1mM E7 peptide, 20:1 E/T ratio. Right panel: inhibition of colony formation
from KCs with or without 1 mm E7 peptide, or from K14-E7 KCs, 25:1 E/T ratio.
(c) H-2b/E7 peptide-specific T-cell lines from C57, perforin/, or Fas-L/
mice at 5:1 E/T ratio. Left panel: lysis of EL4 cells with or without 1 mM E7
peptide. Right panel: inhibition of colony formation from H-2b KCs with or
without 1 mm E7 peptide. (d) H-2b anti-HA (influenza) peptide-specific
cytotoxic T lymphocytes (CTLs) from C57 or perforin/ mice at 5:1 E/T ratio.
Inhibition of colony formation from H-2b KC with or without 1 mm HA
peptide. All results are expressed as meanþ SD and are representative of 2–4
independent assays. **Po0.01, ***Po0.001, ****Po0.0001, NS P40.05.
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Figure 3. Rejection of human papillomavirus type-16 (HPV16) E7 skin grafts
independent of perforin and Fas-L. (a) HPV16-E7 skin was grafted to C57
recipients immunized with E7 protein (IM only B, n¼14), adoptively
transferred with E7TCR splenocytes (AT only ., n¼ 14), or immunized with
E7 protein and adoptively transferred with E7TCR (ATþ IM J, n¼ 35),
Fas-L/ E7TCR (’, n¼20), or perforin/ E7TCR (D, n¼ 15) splenocytes.
Kaplan–Meier survival curves are shown. (b) HPV16-E7 skin grafts were
transplanted onto C57 recipients immunized with E7 protein and adoptively
transferred with E7 peptide-specific cytotoxic T lymphocyte (CTL) lines. CTL
lines were C57 (J, n¼ 12), Fas-L/ (’, n¼ 14), or perforin / (D, n¼ 17).
Kaplan–Meier survival curves are shown.
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to contain other cytokines. To determine whether IFN-g was
the primary cytokine responsible for inhibiting colony
formation, neutralizing antibody to IFN-g or TNF-a was
added to plated KCs exposed to T-cell-conditioned super-
natant. Addition of anti-IFN-g reduced maximal colony
inhibition by the T-cell-conditioned supernatant in a dose-
dependent manner, whereas addition of control rat IgG or
anti-TNF-a had no effect on colony inhibition induced by the
T-cell-conditioned supernatant (Figure 4c and d). From these
data we concluded that IFN-g is the major soluble factor
responsible for inhibition of colony formation by CTL-
conditioned supernatant.
Interferon-c from CTLs is necessary and sufficient to inhibit KC
colony formation in vitro
Taken together, these data show that exogenous IFN-g at
sufficient concentration inhibits KC colony formation. To
determine whether effector cell-derived IFN-g is necessary for
inhibition of KC colony formation by antigen-activated CTLs,
IFN-g/ CTLs and KCs from IFN-g receptor subunit-1
(IFN-gR1/) donors were used in the colony inhibition assay
(Figure 5). Killing of peptide-pulsed EL4 cells and inhibition
of KC colony formation by IFN-g replete or deficient
E7-specific CTL lines was compared. IFN-g/ CTLs were
impaired in their ability to inhibit KC colony formation but
not in their ability to kill EL4 cells (Figure 5a and b). Finally,
CTL-conditioned supernatant was added to C57 or IFN-gR1/
KCs. Colony formation from KCs with intact signaling through
their IFN-gR1 was inhibited by over 70%, whereas colony
formation by IFN-gR1/ KCs was not impaired by the same
supernatants (Figure 5c). Similarly, colony formation from
C57 KCs pulsed with E7 peptide and exposed to E7-specific
T cells was significantly inhibited (75%), whereas colony
formation by KCs not exposed to peptide and by peptide-
pulsed IFN-gR1/ KCs was not affected by co-culture with
E7 peptide-specific CTLs (Figure 5d). These data show that
signaling through IFN-gR1 is necessary for both T-cell-
mediated and CTL-conditioned supernatant-mediated inhibi-
tion of KC colony formation in vitro.
DISCUSSION
This study shows that elimination of epithelium expressing
non-self antigen only in KCs requires CD8 T cells but does
not require perforin, which is generally regarded as a
sufficient effector mechanism for killing cultured cell lines
in vitro and tumors in vivo. It shows further that elimination
of KCs with clonogenic potential concurrently expressing
non-self antigens requires IFN-g signaling to KCs, and can be
achieved by a sufficient concentration of IFN-g in vitro.
Previous studies of T-cell effector function in skin have
focused on rejection of grafts presenting major or minor
histocompatibility antigens (Mason, 1988), or on clearance of
lytic epitheliotropic viruses (Doherty et al., 1997). Major
histocompatibility alloantigens, directly presented by anti-
gen-presenting cells in skin grafts, invoke strong and broad T
effector responses, and either CD4 or CD8 T cells are able to
effect graft rejection (Kobayashi et al., 1992), although CD4
cells are not necessary if CD8 cells are present (Haskova
et al., 2000). Minor alloantigens present on grafted epithe-
lium, provided they are directly presented on bone marrow-
derived cells, can invoke strong immune responses, and are
also rejected by CD8-dependent mechanisms (Oukka et al.,
1997). KCs are capable of processing and presenting antigen
directly (Kim et al., 2009), although transgenic antigens
expressed in KCs can also be cross-presented by local
CD103þ antigen-presenting cells (Bedoui et al., 2009).
The precise effector mechanisms leading to skin graft
rejection by MHC class I- or II-restricted T cells are undefined
(Horner et al., 2008). However, as shown in this study,
neighboring grafts not showing antigen are not damaged by
immune destruction of antigen-bearing grafts, and in an
allophenic MHC class I-restricted mouse model, cell destruc-
tion is specific to the epithelial cells presenting alloantigen
and spares adjacent cells not presenting antigen (Singer and
Rosenberg, 1988), suggesting that epithelial cell and effector
T-cell contact specifically determines cell death. In MHC
class II-restricted models of T-cell killing, perforin, Fas ligand,
or TNF-a are not required, as was observed in this study, in
which killing was however clearly MHC class I restricted (Ito
et al., 1999).
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Figure 4. IFN-c is sufficient to inhibit keratinocyte (KC) colony formation
in vitro. Primary KCs were treated with cytotoxic T lymphocyte (CTL)-
conditioned supernatant (a, c, and d) or recombinant mouse IFN-g (b and e)
from days 4 to 7 of culture. Where indicated, the pan-caspase inhibitor zVAD-
fmk (20mM final) (e) or purified neutralizing monoclonal antibodies against
IFN-g (c) or tumor necrosis factor (TNF)-a (d) were also added. Results are
shown as percentage reduction in colony numbers compared with untreated
KCs, and expressed as meanþ SD. The experiment is representative of two
independent assays. **Po0.01, NS P40.05 treatment versus IFN-g only.
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CD8 effector cells have two broad and non-exclusive cell
contact-dependent effector mechanisms for killing target
cells: perforin/granzyme granule exocytosis and ligation of
TNF-a death receptor family members, including Fas-L and
tumor necrosis factor-related apoptosis-inducing ligand.
Multiphoton microscopy imaging suggests that in vivo, lytic
mechanisms are much slower than those routinely observed
in the in vitro cytotoxicity assays (Boissonnas et al., 2009) and
are likely mediated by more than perforin-mediated damage
to the cell membrane. Although effector mechanisms targeted
at vascular endothelium and antigen-presenting cells may
have a part in rejection of allografts (Valujskikh et al., 2002),
in epithelial tumors, as in this grafting model, direct antigen
presentation is limited to KCs. Within the skin, the majority of
KCs are already terminally differentiated, with no self-
regeneration capacity. Thus, only the epithelial stem cells,
and cytokeratin 15 expressing transit amplifying cells along
the basement membrane, contribute to colony formation and
are effective targets for immunotherapy (Murphy, 2007). The
partial response to caspase inhibition likely reflects sensitivity
of transient amplifying cells to IFN-g-mediated apoptosis,
whereas the epithelial stem cell compartments are resistant to
Fas-mediated apoptosis through expression of the cell
intrinsic caspase-8 inhibitor, the cellular FLICE inhibitory
protein (Armbruster et al., 2009). Bone marrow-derived stem
cells, although susceptible to CD45 antibody-mediated lysis,
generally express low levels of MHC class I (Kim et al., 2005;
Lampton et al., 2008) and are thus relatively resistant to
conventional T-cell lytic mechanisms, although susceptible
to natural killer cell lysis by conventional lytic mechanisms
(Moretta et al., 2003), and epithelial cells along the basement
membrane of the hair follicle, in which stem and
transit amplifying cells reside, similarly express low levels
of MHC (Paus et al., 1999), suggesting that they would be
similarly resistant to lytic mechanisms requiring prolonged
MHC class I-restricted T-cell interactions. Thus, direct T-cell/
KC interactions are unlikely to be sufficient in eliminating
epithelium expressing antigen only in KCs, as observed in
practice in this and other studies that we have conducted
(Frazer, 2008).
IFN-g is a recognized promoter of differentiation of
epithelial KCs (Hancock et al., 1988; Saunders and Jetten,
1994), and of upregulation of MHC expression (Niederwieser
et al., 1988) and antigen presentation by epithelial cells
(Albanesi et al., 1998). In this study, IFN-g alone was
sufficient to suppress the clonogenic potential of KCs
in vitro. In vivo, upregulation of antigen presentation on
KCs by IFN-g would increase the number of cells presenting
antigen to T cells, leading to a positive feedback mechanism
inducing more effector T cells locally to secrete IFN-g
(Wakim et al., 2008; Kim et al., 2009), and thus force
terminal differentiation of the locally susceptible stem cells.
Terminal differentiation of stem cells and apoptosis of
transient amplifying cells, potentially combine to eliminate
epithelium expressing non-self antigen. This mechanism for
elimination of antigen-bearing epithelial tumors and skin
expressing antigen from chronic viral infection is practically
showed by the benefits of IFN therapy for treatment of
persistent HPV infection (Schneider et al., 1995), and of
epithelial tumors (Takaku, 1987). Whether these empiric
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interventions work through the proposed mechanism requires
further study in animal models of these diseases.
MATERIALS AND METHODS
Animals
Inbred mouse strains used in this study, C57BL/6J (H-2b) mice, BALB/c
(H-2d), and FVB/n (H-2q), were obtained from the Animal Resources
Centre (Perth, Australia). Inbred, transgenic mouse strains engi-
neered to express their model antigens in epithelial cells included
C57 mice transgenic for the HPV16-E7 oncoprotein expressed from
the K14 promoter (K14-E7 mice) (Frazer et al., 2001); C57 mice
transgenic for minimal peptide antigens, K14-erSIINFEKL.hGH
(abbreviated K14-OVAp (McGargill et al., 2002)) and K14-erSIYR-
YYGL.hGH (Stefanski et al., 2001), a gift from K.A. Hogquist,
University of Minnesota, MN; and C57 mice transgenic for a
membrane-bound form of OVA (K5-mOVA) (Azukizawa et al.,
2003), a gift from S. Itami (Osaka University, Japan). E7 and
OVA-specific spleen cells were obtained from E7TCR (Narayan
et al., 2009) and Rag1/ OVA TCR (Hogquist et al., 1994)
transgenic mice. Mice deficient in expression of functional perforin,
Fas-L, IFN-g, IFN-gR1, or b2m were purchased from Jackson
Laboratory (Bar Harbor, ME) and bred locally. MHC class I-deficient
K5-mOVA and perforin, functional Fas ligand, or IFN-g deficient
E7TCR mice were obtained by inter-crossing F1 offspring of
homozygous mutant mice and K5-mOVA or E7TCR transgenic
mice, respectively.
Gender-matched mice at 6–12 weeks of age were used as effector
cell donors and skin graft donors and recipients, and were
maintained under conventional conditions in specific pathogen-free
holding rooms in the Princess Alexandra Hospital Biological
Resources Facility. Protocols were approved by the institutional
animal ethics committee.
Skin graft transplantation
Whole-thickness skin was grafted as previously described
(Matsumoto et al., 2004). Grafts were assessed as technically
successful if adherent and vascularized on day 8. Individual grafts
were considered rejected when no viable epidermis was evident.
Grafts were observed at least twice weekly for the duration of
experiments and classified as showing no evidence of rejection if
grafts were intact at day 100.
Combined active/passive immunotherapy for skin graft
rejection
Combined active/passive immunotherapy was administered as
previously described (Matsumoto et al., 2004). In brief, 5.0 106
nucleated spleen cells from TCR transgenic mice or in vitro cultured
CTLs were transferred to skin graft recipients on the day of grafting.
Where indicated, mice were immunized subcutaneously at the tail
base with OVA protein (50 mg per mouse; Sigma Aldrich, St Louis,
MO) or a hexa-histidine HPV16-E7 fusion protein (50 mg per mouse),
prepared in E. coli as previously described (Fernando et al., 1999).
Protein antigens were mixed with 10 mg QuilA (Iscotec AB, Lulea,
Sweden) before injection.
Generation of CTL lines
HPV16-E7 peptide-specific CTL lines were prepared as previously
described, except that spleens were collected 7 days after
immunization rather than 3 weeks (Leggatt et al., 2002). Cells were
used at days 7–10 after stimulation. Alloantigen-specific CTLs were
induced in BALB/c mice by a single subcutaneous immunization
with 2 107 irradiated C57 spleen cells. Donor spleens were
collected after 7–10 days and cultured as described above, except
that allogeneic stimulator cells were irradiated in the absence of
exogenous peptide. Anti-HA (influenza virus hemagglutinin) pep-
tide-specific CTLs were generated exactly as described (Shanker
et al., 2009).
Cell-free CTL supernatant was collected from perforin-deficient
CTLs that had been stimulated with antigen (E7 peptide-pulsed
irradiated syngeneic splenocytes) 7 days previously. The supernatant
was clarified by centrifugation at 3,000 g for 10minutes at 4 1C.
Supernatants collected from the same CTL line over successive
weeks were pooled, filtered through 0.22 mm filter, and stored at
80 1C. CTL-conditioned supernatant was then supplemented into
the test wells with total volume maintained at 2ml per well. Control
supernatant was collected from parallel cultures of perforin-deficient
CTLs expanded as above, except that peptide was omitted from the
irradiated stimulator cells.
Cytotoxicity assay
51Chromium-release cytotoxicity assays with cultured CTL lines and
conventional or KC targets were undertaken, and percentage of
specific lysis was calculated, as described previously (Leggatt et al.,
2002).
KC colony inhibition assay
Primary murine epithelial KCs were isolated as previously
described (Leggatt et al., 2002), and 15–20,000 KCs were added to
each well of a six-well tissue culture plate previously coated with rat
tail collagen. Plates were then incubated for 3 days to allow
adherence and colony formation to commence. Where indicated,
rm-IFN-g (BD-Pharmingen, San Jose, CA, batch-specific activity
1.1 108Umg–1), the pan-caspase inhibitor zVAD-fmk (Promega,
Madison, WI), or control analog zFA-fmk (ICN Pharmaceuticals,
Aurora, OH) was added into the culture media from day 4 to day 7.
BSA (Sigma Aldrich) was used as a control for nonspecific effects of
protein addition. Soluble E7 peptide was added where indicated on
assay day 3. After 24 hours, free peptide was removed by gentle
washing before addition of CTLs at different effector to target ratios.
The assays were typically incubated for a further 3 days at 37 1C.
Additional manipulations included blockade of IFN-g (biotinylated,
clone R4-6A2, BD-Pharmingen), Fas-L (clone MFL4, BD-Pharmin-
gen), or TNF-a (clone G281-2626, BD-Pharmingen) with purified,
neutralizing monoclonal antibodies that were added to wells daily.
Affinity purified rat IgG1 (eBioscience, San Diego, CA) was used as a
control treatment.
When distinct colonies were visible in ‘‘no treatment’’ wells,
assays were terminated and the KC colonies visualized by staining
with Coomassie Blue (0.1% w/v Brilliant blue dye (Sigma Aldrich) in
10% v/v acetic acid and 90% v/v methanol) for 2minutes at room
temperature. Stain was then aspirated from the wells and colonies
were washed with destain buffer (10% v/v acetic acid; 30% v/v
methanol; and 60% v/v water) until distinct colonies were evident.
Plates were allowed to air dry. Percentage reduction in colony number
was calculated as: %reduction in colony counts¼ (mean count (no
treatment)mean count (test))/mean count (no treatment) 100.
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Statistics
Specific lysis and colony inhibition data are expressed as mean±SD.
The statistical significance of differences was determined by two-
tailed, unpaired t-test using GraphPad Prism (version 4.0, La Jolla,
CA) software. Kaplan–Meier plots were used to analyze skin graft
survival, and a log-rank test was used to examine the statistical
significance of differences in the survival curves. Differences with
Po0.05 were considered significant.
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